Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound roxithromycin dispersible tablets for lower respiratory tract infection with viscous sputum
CTR20132644Phase 2Active
- Sponsor
- Hefei Chuandi Pharmaceutical Technology
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roxithromycin in acute bronchitis, chronic bronchitis (CB), community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), pulmonary infection, sponsored by Hefei Chuandi Pharmaceutical Technology. Started Apr 2014; status: active.
02
Drugs
roxithromycin
03
Conditions
acute bronchitischronic bronchitis (CB)community-acquired pneumonia (CAP)hospital-acquired pneumonia (HAP)pulmonary infection
Beyond the preview
Go deeper on CTR20132644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132644.